GNTA - Genenta expands pact with AGC Biologics to make cell therapy products for trials
- Genenta Science ( NASDAQ: GNTA ) signed an agreement with AGC Biologics to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs.
- Genenta had an existing manufacturing services agreement (MSA) with Molecular Medicine's facility in Milan, which was acquired by AGC in 2020. The Milan site has been manufacturing lentiviral vectors (LVV) and drug product for Genenta's ongoing programs since 2016, according to the company.
- "The expansion of our existing relationship with AGC Biologics underscores the progress of our platform's clinical development. Based on results from Phase 1 of the ongoing Phase 1/2 clinical trial, we are scaling up the manufacturing process to be ready for Phase 2 of the trial," said Genenta CEO Pierluigi Paracchi.
For further details see:
Genenta expands pact with AGC Biologics to make cell therapy products for trials